Wedbush maintains Crescent Biopharma $27 price target
Wedbush maintained a $27.00-per-share price target for Crescent Biopharma, per Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.